Back

Percentage and main features of patients referred to a cardiac rehabilitation program who would have an indication for a GLP1 receptor agonist based on the SELECT trial criteria

25 April 2024 (09:00 - 12:30)
Organised by: Logo
Congress Presentation Part of: Poster session 1 - Managing cardiovascular risk: pharmacological and digital tools Secondary Prevention Open Access ESC Preventive Cardiology 2024 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Doctor Joan Torres Marques

Son Llatzer University Hospital, Palma de Mallorca (Spain)

5 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor P. Poggio (Milan, IT)
Abstract Slides
Presentation thumbnail
Professor A. Abreu (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Mr D. Tsounis (Nea Makri, GR)
Abstract
Presentation thumbnail
Professor N. Mouine (Rabat, MA)
Abstract Slides

Access the full session

Session thumbnail
Poster session 1 - Managing cardiovascular risk: pharmacological and digital tools

The Event

Event poster

ESC Preventive Cardiology 2024

25 April 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
GLP-1 receptor agonists as an opportunity for patients with atherosclerotic cardiovascular disease as well as obesity in Germany
thumbnail
Congress Presentation
Characteristics of overweight and obese patients undergoing a cardiac rehabilitation program.
thumbnail
Webinar
GLP-1 RAs and HFpEF : what do we know from large RCTs about GLP-1 RAs and their effects on HFpEF?

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources